Prasterone

How the Relationship Between DHT and DHEA Shapes Men’s Health Understanding the relationship between DHT and DHEA helps patients see hormones not as isolated numbers, but as interconnected systems driving vitality and health.” — Chris Rue, FNP-C METAIRIE, LA, UNITED STATES, September 2, 2025 / EINPresswire.com / -- DHEA is often called the “mother hormone” because it serves as a precursor for many other hormones, including testosterone and estrogen. From testosterone, the enzyme 5-alpha-reductase creates DHT, one of the most potent and active androgens in the body. The relationship between DHT and DHEA is a perfect example of how hormones work together in a cascade. DHEA lays the foundation, while DHT delivers powerful effects on tissues such as muscles, bones, and the reproductive system. When either one falls out of balance, men may experience fatigue, low libido, mood changes, or muscle decline. At MOPE Clinic, providers assess both hormones as part of a full-spectrum hormone evaluation. By looking at the entire hormonal cascade, the clinic helps patients restore balance and improve their quality of life. What Is DHEA? Dehydroepiandrosterone (DHEA) is produced mainly in the adrenal glands. Levels peak in early adulthood and naturally decline with age, often falling sharply by the time men reach their 40s or 50s. Because DHEA converts into both testosterone and estrogen, a drop in DHEA can reduce downstream hormones, including DHT. Low DHEA has been associated with: Fatigue and poor stamina Decreased sexual desire Lower mood and irritability Weakened immune response Loss of muscle mass and strength Optimizing DHEA through lifestyle, supplementation, or medically guided therapy can help restore balance across the entire hormone network. What Is DHT? Dihydrotestosterone (DHT) is derived from testosterone and is often misunderstood. While it is best known for contributing to male pattern baldness, its role in men’s health extends far beyond hair. DHT strongly binds to androgen receptors, making it more potent than testosterone in some tissues. DHT contributes to: Pubertal development and sexual differentiation Libido and erectile function Muscle strength and bone density Fat distribution and metabolic health Confidence, focus, and mental drive Although too much DHT can contribute to prostate growth or hair thinning in genetically susceptible men, balanced levels are crucial for vitality and performance. Benefits of DHT and DHEA Balance for Hormone Optimization When DHEA and DHT are in balance, men experience improved health and well-being. The synergy between these two hormones supports: Sexual function – DHT enhances libido and sexual performance, while DHEA contributes to sexual desire and stamina. Physical strength – Together, they promote lean muscle growth, stronger bones, and faster recovery after exercise. Mental clarity – Balanced levels are linked with sharper focus, greater resilience, and better mood stability. Healthy metabolism – DHEA influences fat metabolism, and DHT encourages lean muscle retention, which boosts energy use. This combined impact highlights why the relationship between DHT and DHEA matters so much in hormone optimization. Addressing Hair and Prostate Concerns Understandably, many men worry about the effects of DHT on hair and prostate health. Genetics play a strong role in male pattern baldness, and while DHT contributes, it is not the sole cause. Similarly, prostate enlargement can be influenced by DHT, but lifestyle, genetics, and other hormones also matter. MOPE Clinic helps patients navigate these concerns by carefully monitoring hormone levels and tailoring treatment. The goal is to preserve the benefits of DHT while minimizing unwanted side effects. Treatments may include DHEA supplementation, testosterone therapy, lifestyle modifications, or advanced peptide therapies depending on the individual’s needs. Cognitive and Emotional Benefits Hormones impact the brain just as much as the body. DHEA supports resilience against stress, while DHT enhances confidence and mental clarity. Together, they improve overall well-being. Emerging research even suggests that healthy androgen balance may reduce the risk of neurodegenerative decline. Patients who restore optimal DHEA and DHT levels often report clearer thinking, stronger memory, and steadier moods. Lifestyle Practices That Support Hormonal Balance MOPE Clinic emphasizes that medical treatment works best alongside healthy lifestyle choices. Natural ways to support DHEA and DHT levels include: Resistance training – Builds muscle and boosts androgen activity. Proper sleep – Restorative sleep helps regulate adrenal and gonadal hormones. Stress management – Reduces cortisol’s negative impact on hormone production. Nutrient-dense diet – Provides essential fats and proteins for hormone synthesis. When lifestyle changes are not enough, medical interventions ensure safe and effective hormone optimization. MOPE Clinic’s Approach to Managing DHT and DHEA At MOPE Clinic, providers understand that every patient’s hormone profile is unique. Rather than using a one-size-fits-all approach, the clinic combines advanced lab testing with personalized treatment. By evaluating DHEA, testosterone, estradiol, cortisol, and DHT together, practitioners identify imbalances and design targeted plans. Ongoing monitoring ensures patients achieve long-term improvements in energy, body composition, libido, and mood. Why Education Is Key Misinformation about hormones often causes unnecessary fear. By educating patients, MOPE Clinic empowers them to make informed decisions. Understanding the relationship between DHT and DHEA helps patients see hormones not as isolated numbers, but as interconnected systems driving vitality and health. About MOPE Clinic MOPE Clinic, led by Chris Rue, FNP-C, specializes in hormone replacement therapy, weight management, and peptide optimization. Based in Metairie, Louisiana, MOPE Clinic delivers evidence-based, personalized care that restores balance and enhances overall wellness. For more information, visit https://mopeclinic.com or call 504-322-3888 to schedule a consultation. Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 info@mopeclinic.com Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of sigmar-1 receptor (S1R/SIGMAR1) through blarcamesine activation, titled “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.”1 The mechanistic confirmation that blarcamesine restores impaired autophagy through S1R/SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level was previously established both in vitro and in vivo. Specifically, studies demonstrated enhanced autophagic flux in human cells and in C. elegans as well as increased proteostasis capacity, ultimately ameliorating paralysis caused by protein aggregation in C. elegans. In that study the widely published reference S1R agonist PRE-084 demonstrated the same autophagy restorative effect as established with blarcamesine, strengthening the rationale that the activation is analogous in both drugs.2 This new publication confirms with additional biochemical data in more detail the autophagy restoration mechanism of S1R activation with blarcamesine. The specific S1R-localized motif responsible for physiologically relevant interactions with autophagy proteins—promoting autophagosome biogenesis, autophagic cargo reception, and lysosome fusion—was confirmed and modulated by blarcamesine. “We are excited about the ability to confirm the more precise mechanism of autophagy restoration through oral blarcamesine, which has demonstrated very persuasive clinical data in early Alzheimer’s disease,” said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. “The interaction reported in this study could represent a missing biochemical link in autophagy modulation by S1R.” S1R/SIGMAR1 has emerged as one of the prominent targets in treating neurodegeneration. It promotes autophagy and results in the degradation of amyloid-beta precursor protein (APP), thereby normalizing Aβ production.3 S1R/SIGMAR1 activation promotes neurogenesis, reduces reactive oxygen species (ROS) formation, suppresses neuroinflammation, and ameliorates Aβ toxicity. S1R/SIGMAR1 is also involved in maintaining endoplasmic reticulum (ER) function and regulating calcium.4 Data suggest that activation of S1R/SIGMAR1 results in the restoration of homeostatic function within the body and is pivotal to restoring neural cell balance and promoting neuroplasticity.5 Recent studies with Anavex compounds, blarcamesine (ANAVEX®2-73) and ANAVEX®3-71 show that S1R/SIGMAR1 activation also involves mitochondrial performance, an intricate phenomenon that provides energy for cellular functions.6 S1R/SIGMAR1 agonists, including blarcamesine (ANAVEX®2-73) and ANAVEX®3-71, have been reported to reduce toxic Aβ, tau, and neuroinflammation.7 “This independent paper elucidates more clearly the blarcamesine-activated S1R/SIGMAR1 direct interference with the autophagic process, by functioning as direct autophagy receptor and hence explaining the relevance of restoring impaired autophagy as early event, preceding amyloid-beta and tau as a compensatory mechanism to chronic CNS diseases, especially Alzheimer’s disease,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. The paper can be accessed online at: https://www-sciencedirect-com.sutd.idm.oclc.org/science/article/pii/S2589004225015482. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information:Anavex Life Sciences Corp.Research & Business DevelopmentToll-free: 1-844-689-3939Email: info@anavex.com Investors:Andrew J. BarwickiInvestor RelationsTel: 516-662-9461Email: andrew@barwicki.com 1 Baeken et al. “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.” iScience Volume 28, Issue 9, 2025, 113287.2 Christ, M G et al. “Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo.” Cells vol. 8,3 211. 2 Mar. 2019.3 Jaeger PA, Pickford F, Sun C-H, et al. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PloS one. 2010;5(6):e11102.4 Nguyen L, Lucke-Wold BP, Mookerjee SA, et al. Role of sigma-1 receptors in neurodegenerative diseases. Journal of pharmacological sciences. 2015;127(1):17-29; Moriguchi S, Shinoda Y, Yamamoto Y, et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PloS one. 2013;8(4):e60863-e60863; Rosen DA, Seki SM, Fernández-Castañeda A, et al. Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Translational Medicine. 2019;11(478):eaau5266; Maurice T, Volle J-N, Strehaiano M, et al. Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ1 receptors. Pharmacological research. 2019;144:315-330.5 Advances in Experimental Medicine and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.6 Goguadze, N., Zhuravliova, E., Morin, D., Mikeladze, D., & Maurice, T. (2019). Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress. Neurotoxicity research, 35(1), 1–18.7 Lahmy V, Meunier J, Malmström S, et al. Blockade of Tau hyperphosphorylation and Aβ 1–42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ 1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2013;38(9):1706-1706; Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Medeiros R. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Neurodegener Dis. 2016;16(1-2):95-110.